Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC? Which Patients Benefit Most From Adjuvant Atezolizumab in NSCLC?

A new analysis of data from IMpower010 has sparked a debate over which patients with early non-small cell lug cancer benefit most.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news